股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 2. 股份分類 | 其他分 ...

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 2. 股份分類 | 其他分類 ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：575) NOTIFICATION LETTER 通知信函 23 September 2025 Dear Non-registered Shareholder(s)(Note 1), Regent Pacific Group Limited (the "Company") － 二零二五年中期報告（「是次公司通訊」）之發佈通知 是次公司通訊之中、英文版本已上載於本公司網站(www.regentpac.com)及香港聯合交易所有限公司披露易網站(www.hkexnews.hk)，歡迎查閱。 – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication is available ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：575) NOTIFICATION LETTER 通知信函 23 September 2025 Yours faithfully, For and on behalf of Regent Pacific Group Limited Jamie Gibson Executive Director Dear Registered Shareholder(s), Note: Corporate communications refer to all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) annual and interim reports (and all reports and financial statem ...

CONTENTS 目錄 • A reduced loss attributable to shareholders of the Company of approximately US$2.22 million, which was mainly attributable to the Group's operating and R&D expenses of approximately US$2.25 million. • In respect of the progress being made with Senstend™ in the PRC, the main objective remains for Wanbang Biopharmaceutical to obtain marketing approval by the end of 2025, with first commercial launch projected to start in Q1 2026. If the NMPA grants an import licence for Senstend™, US$5 million ( ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 2. 股份分類 | 其他分類 ...

Summary of Key Points Core Viewpoint - The company reported a shareholder loss of approximately $2.215 million for the six months ending June 30, 2025, compared to a loss of about $2.621 million in the same period last year [1] Group 1: Financial Performance - The company's shareholder loss decreased from $2.621 million to $2.215 million year-on-year [1] Group 2: Product Development - The main goal of Jiangsu Wanbang Pharmaceutical is to obtain market approval for Senstend™ in China by the end of 2025, with expectations for commercial launch in the first quarter of 2026 [1] - If the National Medical Products Administration grants an import license for Senstend™, Jiangsu Wanbang Pharmaceutical will need to pay the group $5 million (before Chinese withholding tax) [1] - After the first commercial sale of Senstend™ in China, Jiangsu Wanbang Pharmaceutical will owe the group an additional $2 million (before Chinese withholding tax) [1] Group 3: Clinical Research - The company has evaluated proposals from two well-known clinical research institutions regarding the Phase III clinical study of Fortacin™ in the United States and is in discussions with several pharmaceutical companies about licensing Fortacin™ in the U.S. market [1]

Core Viewpoint - The company reported significant revenue growth and a reduction in net loss for the six months ending June 30, 2025, indicating improved financial performance [1] Financial Performance - The group's revenue reached 237 million USD, representing a year-on-year increase of 92.68% [1] - The net loss narrowed to 2.215 million USD, a decrease of 15.49% compared to the previous year [1] - Earnings per share showed a loss of 0.961 cents [1]

Core Viewpoint - Lijinjing Pacific (00575) reported a significant increase in revenue and a reduction in net loss for the six months ending June 30, 2025, indicating improved financial performance [1] Financial Performance - The group's revenue reached $237,000, representing a year-on-year growth of 92.68% [1] - The net loss narrowed to $2.215 million, a decrease of 15.49% compared to the previous year [1] - Earnings per share showed a loss of 0.961 cents [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：���） 截至二零二五年六月三十日止六個月之 未經審核中期業績 業績概覽 截至二零二五年六月三十日止六個月之財務業績概要及其他重要事件包括： – 1 – • 本公司股東應佔虧損減少約2,220,000美元，主要是由於本集團的營運及研 發開支約2,250,000美元。 • Senstend™於中國的進展方面，江蘇萬邦醫藥的主要目標仍為於二零二五年 底前獲得入市批准，並預計於二零二六年第一季度開始首次商業化上市。倘 國家藥品監督管理局授予Senstend™進口許可證，江蘇萬邦醫藥將須向本集 團支付5,000,000美元（扣除中國預扣稅前）。此外，Senstend™於中國進行首 次商業銷售後，江蘇萬邦醫藥將須向本集團支付2,000,000美元（扣除中國預 扣稅前）。 • Fortacin™於美國的進展方面，本公司已評估兩家知名臨床研究機構（「臨床 研究機構」）關於 ...